The FDA approved Arvinas and Pfizer’s Veppanu (formerly vepdegestrant) for a defined subgroup of adults with metastatic estrogen receptor–positive, HER2-negative breast cancer that progressed after at least one endocrine therapy and carries ESR1 mutations. Regulatory review was based on the VERITAC-2 trial, where Veppanu improved progression-free survival by nearly three months versus fulvestrant in the approved population. The decision underscores growing clinical validation for targeted protein degradation—medicines that eliminate disease-linked proteins rather than only blocking them—while also narrowing the label to a biology-defined segment where the benefit was demonstrated.